Genocea Biosciences Reports First Quarter 2015 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the first quarter ended March 31, 2015.

"2015 is an important year for Genocea with significant clinical data readouts upcoming for both our lead programs. Top-line Phase 2 data for GEN-003, for the treatment of genital herpes, is expected this quarter.

Help employers find you! Check out all the jobs and post your resume.

Back to news